Last Updated: 28 Aug 2025
Source: Statifacts
Liquid Biopsy Products Market (By Type: CTCs, ctDNA, and Exosomes; By Application: Hospitals and Clinics, Third-party Laboratories, and Other; By Region: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) Industry Size, Share, Growth, Trends 2025 to 2034.
The global liquid biopsy products market size accounted for USD 5.14 billion in 2024 and is predicted to touch around USD 16.7 billion by 2034, growing at a CAGR of 12.5% from 2025 to 2034. Driven by critical product segments and diverse end-use applications. The liquid biopsy products market is undergoing rapid growth, attributed to increasing cancer incidences and the rising demand for non-invasive diagnostic options.
| Reports Attributes | Statistics |
| Market Size in 2024 | USD 5.14 Billion |
| Market Size in 2025 | USD 5.79 Billion |
| Market Size in 2031 | USD 11.73 Billion |
| Market Size by 2034 | USD 16.7 Billion |
| CAGR 2025 to 2034 | 12.5% |
| Base Year | 2024 |
| Forecast Period | 2025 to 2034 |
The market continues to see a strong uptake of multiplexed liquid biopsy tests utilizing next-generation sequencing techniques augmented by artificial intelligence, allowing for earlier and robust multi-biomarker detection for optimal clinical outcomes on a worldwide basis. While the growing incidence of cancer, developing personalized medicine practices, increasing reliance from pharmaceuticals on companion diagnostics, and an increasing awareness of oncological early detection is helping drive global demand for liquid biopsy products, some barriers remain towards broader adoption; their high cost, limited reimbursement landscape, regulatory hurdles, and differences in advanced diagnostic infrastructure remains a limitation for widespread adoption especially in emerging markets and rural health systems. Opportunities remain to broaden clinical applications for prenatal testing, transplant monitoring for solid organ rejection, minimal residual disease detection, and advances utilizing AI to build advanced profiles of circulating tumour DNA and exosomes to improve clinical specificity on a global basis.
| Regions | Shares (%) |
| North America | 45% |
| Asia Pacific | 22% |
| Europe | 25% |
| LAMEA | 8% |
| Segments | Shares (%) |
| CTCs | 30% |
| ctDNA | 55% |
| Exosomes | 15% |
| Segments | Shares (%) |
| Hospitals and Clinics | 50% |
| Third-party Laboratories | 35% |
| Other | 15% |
Published by Kesiya Chacko
